Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 14/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 14/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29347849 | 0.83 | MAPT (0.38) | PIK3CAMAPTCASP1AURKATTK | |
| SCHEMBL16133709 | 0.78 | GABRA1 (0.35) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL15292546 | 0.78 | PIK3R1 (0.36) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL28649665 | 0.77 | GABRA1 (0.41) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL22959247 | 0.77 | PIK3R1 (0.35) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL11890406 | 0.77 | TSHR (0.43) | PIK3R1PIK3CAP2RX3P2RX2 | |
| SCHEMBL29527128 | 0.77 | PIK3R1 (0.35) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL29527168 | 0.77 | GABRA1 (0.41) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL15150582 | 0.77 | P2RX3 (0.35) | PIK3R1PIK3CAP2RX3P2RX2MAPT | |
| SCHEMBL8986074 | 0.75 | MAPT (0.56) | PIK3CAMAPTCASP1AURKATTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527798-B2 | Cyclopropylboronic compounds, preparation process thereof and use thereof | DIVERCHIM (FR) | 2016-12-27 | — | — | US | disclosed |
| US-9527798-B2 | Cyclopropylboronic compounds, preparation process thereof and use thereof | DIVERCHIM (FR) | 2016-12-27 | — | — | US | disclosed |
| CN-102548984-B | The inhibitor of PI3 kinases and/or MTOR | AMGEN INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2015-11-19 | — | — | US | disclosed |
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2015-11-19 | — | — | US | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | PIK3R1 9/4885PIK3CA 2/4885P2RX3 2600/4885 |
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | HMBS, MMAB, FDPS | PIK3R1 4661/4885PIK3CA 2080/4885P2RX3 4037/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | PIK3R1 9/4885PIK3CA 2/4885P2RX3 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.